Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Clopidogrel and the possibility of drug-drug interaction in primary health care.

Urtane I, Aitullina A, Pukite K.

J Young Pharm. 2013 Mar;5(1):18-21. doi: 10.1016/j.jyp.2013.01.002.

2.

Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.

Harvey A, Modak A, Déry U, Roy M, Rinfret S, Bertrand OF, Larose É, Rodés-Cabau J, Barbeau G, Gleeton O, Nguyen CM, Proulx G, Noël B, Roy L, Paradis JM, De Larochellière R, Déry JP.

J Breath Res. 2016 Jan 27;10(1):017104. doi: 10.1088/1752-7155/10/1/017104.

PMID:
26815196
3.

Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).

Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML.

JACC Cardiovasc Interv. 2013 Dec;6(12):1275-81. doi: 10.1016/j.jcin.2013.06.014.

4.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Drepper MD, Spahr L, Frossard JL.

World J Gastroenterol. 2012 May 14;18(18):2161-71. doi: 10.3748/wjg.v18.i18.2161. Review.

5.

Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.

Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M, Gaussem P.

Arch Cardiovasc Dis. 2013 Dec;106(12):661-71. doi: 10.1016/j.acvd.2013.09.002.

6.

Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q.

Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. Review.

7.

Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.

Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG.

Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404. doi: 10.1097/MEG.0b013e3283460110.

PMID:
21464720
8.

Thienopyridines and statins: assessing a potential drug-drug interaction.

Neubauer H, Mügge A.

Curr Pharm Des. 2006;12(10):1271-80. Review.

PMID:
16611111
9.

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

Furuta T, Iwaki T, Umemura K.

Br J Clin Pharmacol. 2010 Sep;70(3):383-92. doi: 10.1111/j.1365-2125.2010.03717.x.

10.

Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.

Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL.

J Am Coll Cardiol. 2009 Sep 22;54(13):1149-53. doi: 10.1016/j.jacc.2009.05.050.

11.

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2009 Apr;101(4):714-9.

PMID:
19350116
12.

Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.

Ohbuchi M, Noguchi K, Kawamura A, Usui T.

Xenobiotica. 2012 Jul;42(7):633-40. doi: 10.3109/00498254.2011.653655.

PMID:
22313038
13.

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?

Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, Gross M.

Eur J Med Res. 2010 May 18;15(5):220-4.

14.

Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.

Neubauer H, Engelhardt A, Krüger JC, Lask S, Börgel J, Mügge A, Endres HG.

J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7. doi: 10.1097/FJC.0b013e3181e19739.

PMID:
20410834
15.

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH.

Thromb Haemost. 2010 May;103(5):920-5. doi: 10.1160/TH09-08-0516.

PMID:
20352154
16.

Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.

Tran M, Tafreshi J, Pai RG.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):326-37. doi: 10.1177/1074248410369109. Review.

PMID:
20938037
17.

Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.

Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, Jinnai T, Ikeda T, Shirakawa R, Kimura T, Horiuchi H.

J Atheroscler Thromb. 2012;19(6):559-69.

18.

Proton pump inhibitor and clopidogrel interaction: fact or fiction?

Laine L, Hennekens C.

Am J Gastroenterol. 2010 Jan;105(1):34-41. doi: 10.1038/ajg.2009.638. Review.

PMID:
19904241
19.

Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review.

Kwok CS, Loke YK.

Drug Saf. 2012 Feb 1;35(2):127-39. doi: 10.2165/11594900-000000000-00000. Review.

PMID:
22204719
20.

[Proton pump inhibitors and clopidogrel: a hazardous association?].

Szymezak J, Gaussem P.

Rev Med Interne. 2013 Feb;34(2):99-104. doi: 10.1016/j.revmed.2012.11.001. French.

PMID:
23200799
Items per page

Supplemental Content

Support Center